Study of Bleeding With Extended Administration of an Oral Contraceptive


This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described.

Full Title of Study: “Open-Label Study of Cycle Control With Extended Administration of Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 Mcg Oral Tablets”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2007


  • Drug: Norethindrone 1 mg / ethinyl estradiol 20 mcg

Clinical Trial Outcome Measures

Primary Measures

  • Number of bleeding/spotting days/episodes per treatment cycle

Secondary Measures

  • Satisfaction

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy women – Age 25-40 – History of regular cycles Exclusion Criteria:

  • Current or recent (within 2 months) users of hormonal contraceptives – Contraindications for use of hormonal contraception – Conditions which affect the absorption or metabolism of steroid hormones – BMI > 35

Gender Eligibility: Female

Minimum Age: 25 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Warner Chilcott
  • Provider of Information About this Clinical Study
    • Herman Ellman, MD, Warner Chilcott
  • Overall Official(s)
    • Herman Ellman, MD, Study Director, Sponsor GmbH

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.